

## RESEARCH ARTICLE

# Clinicopathological Features and Survival Rate of Colorectal Adenocarcinoma Patients with and without a KRAS Mutation: a Five-Year Study in Yazd, Iran

Shokouh Taghipour Zahir<sup>1\*</sup>, Mohammadreza Nazemian-Yazdi<sup>2</sup>, Peyman Arasteh<sup>3</sup>, Mohammadreza Mortazavizadeh<sup>4</sup>, Mohammad Karbalaieian<sup>1</sup>, Malihe Zare-Mehrjardi<sup>1</sup>

## Abstract

**Background:** By some estimates, colorectal carcinoma is the third most common cancer worldwide. The most appropriate method of treatment, especially of its metastatic form, is determined based on KRAS status. The present study was conducted on patients with colorectal cancer positive or neagtive for a KRAS mutation in terms of survival rate and the response to treatment. **Materials and Methods:** Medical records of all cases with colorectal cancer hospitalized from 2010 to 2015 and with KRAS testing results were studied. Data such as gender, age, tumor (size, grade, location, stage), treatment type, KRAS status and survival were considered as variables. Survival analysis was performed using the Kaplan-Meier method and Log-rank test. Statistical significance level was defined as P value <0.05. **Results:** Out of 90 patients, 55 (61.2%) were male and 35(38.8%) were female with the age range of 22-87 years. The overall disease specific survival was 53±3 (Mean ± SE) months with 95% CI:47-60, and there were statistically significant differences between the mean survival rate with tumor stage and the response to treatment (log rank test, PV=0.007 and PV=0.001) respectively. The risk of mortality was 2.02 times higher in patients with mutant KRAS compared to those with the wild type of the gene; however, this difference was not statistically significant (OR=2.016; 95% CI: 0.68-5.9; PV=0.197). **Conclusions:** In our study the overall 5-year disease specific survival rate was low as compared to similar studies elsewhere. Significant correlations were found between survival time with treatment type and tumor stage.

**Keywords:** Colorectal carcinoma - survival - KRAS - treatment type - tumor stage

*Asian Pac J Cancer Prev*, 17 (7), 3417-3422

## Introduction

Colorectal cancer is the third most common type of cancer among men and women worldwide (world cancer report., 2014; Ferlay et al., 2014). In Iran, colorectal cancer is the third most common cancer among men and the fourth most common among women (Shaib et al., 2013; Cunningham et al., 2010). The prevalence of this cancer has been reported as 1.4 times higher among men than among women (world cancer., 2014; SEER., 2014).

The 5-year survival rate of colorectal cancer varies in different countries, and this rate has been reported in less than 60% of the cases in Europe and in about 65% of the cases in the United States (SEER., 2014; Howlader et al., 2012). The mean survival rate for this cancer seems to be directly correlated with the tumor stage at the time of the

patient's hospital admission, as in stage 0 of the disease (TNM stage Tis, N0, M0), the 5-year survival rate is reported in 100% of the cases, while it drops below 70.8% with lymph node involvement (stage III A, B, C) and less than 13% in stage IV (A, B) of the disease (Howlader et al., 2012; Kolahdoozan et al., 2010; Dolatkah 2015). Colorectal cancer tends to affect people over the age of 50 (world cancer report., 2014).

Its treatment options include surgery, chemotherapy, radiotherapy, neo-adjuvant therapy and targeted therapy (Mohammadipanah 2015). Epidermal growth factor receptor is a membrane bound receptor tyrosine kinase(RTK), with an important role in cancers initiation and progression. Now today the Kirsten rat sarcoma-2 viral (v-Ki-ras2) oncogene homologue (KRAS) protein has been well known as a target of therapy by anti epidermal

<sup>1</sup>Pathology Department, <sup>2</sup>Internal Medicine Department, Shahid Sadoughi University of Medical Sciences, <sup>4</sup>Hematology and Oncology Department, Azad Medical University, Yazd, <sup>3</sup>MPH Department, Shiraz University of Medical Sciences, Shiraz, and Non-Communicable Disease Research Center, Fasa University of Medical Sciences, Fasa, Iran \*For correspondence: taghipour@ssu.ac.ir, taghipourzahirsh@gmail.com

growth factor receptor inhibitor, which in humans is encoded by the KRAS gene (located on the short arm of chromosome 12 at position 12.1) (Mohammadpanah 2015; McGrath et al., 1983; Misale et al., 2012; Allegra et al., 2016). This proto-oncogene could be mutated in some patients with colorectal carcinoma (30-50%) and the result of this mutation is lack of responsiveness to treatment by anti epidermal growth factor receptor inhibitors (Kito and Yamazaki 2015; Deng et al., 2015). In colorectal carcinoma the presence or absence of KRAS mutations has become the main focus of researchers and clinicians in this area and has affected their decisions about the proper types of treatment available to this group of patients and, in recent years, anti-epidermal growth factor receptor treatments are no longer used in the treatment of patients with mutated KRAS (30-40% of the cases) (Yaeger et al., 2015; Vauthey et al., 2013). However, given the different reports on the effect of this treatment on the prognosis of colorectal cancer, the present study was conducted on colorectal cancer patients to find out the differences in survival and recovery rate based on KRAS mutation status.

## Materials and Methods

In this retrospective study hospital folders of all colorectal cancer patients admitted to oncology and pathology wards affiliated with Shahid Sadoughi University of Medical Sciences from March 2010 to April 2015 in Yazd, Iran were reviewed. The study was approved by the Research Ethics Committee of the school of Medicine. Although the study only included a review of patient's records obtained as part of the routine medical care, patients consent forms were obtained when they were first hospitalized. It is a general policy of Shahid Sadoughi affiliated health care centers to obtain a written consent form from the patients upon their freewill, agreeing that their medical records can be used for research purposes. Patient's data confidentiality was maintained and no data regarding patient's personal information were disclosed. The inclusion criteria for entering the study was: all the patients diagnosed with colorectal carcinoma who had a record in the pathology and oncology departments with KRAS test result. All the records that had missing data (including test results) or a written consent form was not obtained, were excluded from the study. In result 90 records were identified and included in the study.

Patient's data were extracted using a checklist which included: age, gender, date of reference and diagnosis, date of death, KRAS status, size and place of tumor, tumor stage, patient's treatment type and grade of tumor. Patient's telephone number and place of residence were also extracted for further follow-ups and assessing patient's survival rates.

### Definition of variables

The site of tumor involvement was divided into four regions including: the rectum, right colon, left colon and the transverse colon. Tumors were classified into 3 groups divided by size, including a group less than 5 cm (Group 1), 5-10 cm tumors (Group 2) and a group with tumors larger than 10 cm (Group 3). The grading of the tumors

was done based on their differentiation pattern including: Well (>95% gland forming), Moderate (50-95% gland forming) and Poor (0-49% gland forming). Tumor staging was performed by using TNM staging system of colorectal carcinoma (TNM/AJCC-7th Edition) into stages: I, II, III, IV and their subgroups. The KRAS and NRAS status results were extracted from patient's hospital records which was divided into two groups including: Wild-type (KRAS and NRAS) and Mutant (KRAS and NRAS) group by using the PCR method (PARTOLAB Pathology Laboratory Molecular Diagnostic Division, Tehran, Iran).

### Treatment type

Patients treatment method was extracted from their hospital records which was based on the presence or absence of metastasis; as patients without metastasis were treated by FOLFOX regimen (Folinic acid, Fluorouracil, Oxaliplatin) (Treatment type 1), and patients with metastasis were treated with respect to their KRAS type, i.e. patients with the wild type of the gene were treated by a combination of FOLFOX and Cetuximab (Treatment Type 2), while patients with mutant KRAS had received a combination of FOLFOX and Bevacizumab as their select treatment (Treatment type 3). FOLFIRI treatment containing Folinic acid, Fluorouracil and Irinotecan was used for patients who experienced complications related to Oxaliplatin. For evaluation of response to treatment, patients were also classified into two groups based on its effect on reduction of the patient's serum CEA levels, elimination of metastasis and tumor shrinkage, including: group 1, showing an appropriate response to treatment, and group 2, showing a lack of response to treatment.

Following pathology and oncology evaluation, patients were contacted via telephone to acquire information regarding their current status. Follow-up time was the interval between diagnosis time and the time of death or last contact with the patient.

### Statistical analysis

The data analysis was done using the SPSS software version 17 for windows (SPSS Inc., Chicago, IL, USA). Patient's data were compared and analyzed using the Chi-square test and for calculating the survival fraction and assessing the effect of different factors on the survival of the patients, the Kaplan-Meier and the Log rank tests were used, respectively. The descriptive data of the patients were compared using their frequency, mean and standard deviation. The odds ratio was measured with a Confidence interval (CI) of 95% to estimate the risk of mortality based on the KRAS status. A two-tailed p-value of less than 0.05 was considered as statistically significant.

## Results

Among the 90 cases whom enrolled in this study, 55 (61.2%) were male and 35 (38.8) were female, with the age range of 22-87 and (mean±SD) age of 56±14 years. The male to female ratio was approximately 1.6:1. Baseline characteristics of 90 patients with colorectal adenocarcinoma are shown in Table 1. As for the KRAS status, 54 (60%) had a wild type KRAS and 36 (40%) had

**Table 1. Patient Characteristics Based on KRAS Status**

Characteristics	Characteristics	KRAS status		Total N (%)	P value		
		Wild N (%)	Mutant N (%)				
Age	Female	22-54	12(63.2)	7(36.8)	19(100)	0.968	
		55-87	10(62.5)	6(37.5)	16(100)		
	Male	22-54	17(68)	8(32)	25(100)		0.178
		55-87	15(50)	15(50)	30(100)		
Gender	Female	22 (62.9)	13 (37.1)	35 (100)	0.659		
	Male	32 (58.2)	23 (41.8)	55 (100)			
Tumor size	1	30 (62.5)	18 (37.5)	48 (100)	0.85		
	2	11 (68.8)	5 (31.3)	16 (100)			
	3	1 (100)	0 (0)	1 (100)			
Tumor location	Rectum	15 (71.4)	6 (28.6)	21 (100)	0.591		
	Right colon	11 (52.4)	10 (47.6)	21 (100)			
	Transverse	7 (53.8)	6 (46.2)	13 (100)			
	Left colon	15 (62.5)	9 (37.5)	24 (100)			
Stage	1	2 (100)	0 (0)	2 (100)	0.309		
	2	28 (68.3)	13 (31.7)	41 (100)			
	3	12 (60)	8 (40)	20 (100)			
	4	10 (47.6)	11(52.4)	21 (100)			
Grade	1	20 (62.5)	12 (37.5)	32 (100)	0.813		
	2	19 (54.3)	16 (45.7)	35 (100)			
	3	1 (50.0)	1 (50.0)	2 (100)			
Metastasis	Yes	21(53.8)	18 (46.2)	39 (100)	0.348		
	No	30 (63.8)	17 (36.2)	47 (100)			
Treatment type	1	30 (62.5)	18 (37.5)	48 (100)	0.001*		
	2	22 (100)	0 (0)	22 (100)			
	3	0 (0)	18 (100)	18 (100)			
Out come	Yes	37 (75.5)	19 (59.1)	56 (100)	0.124		
	No	12 (24.5)	13 (40.6)	25 (100)			

\* Chi-square test

**Table 2. Univariate Prognostic Analysis of Overall Survival**


Characteristics	Survival time (mean ±SE)	95%CI	Survival time (Median ±SE)	95% CI	Total	Number events (N)	Number censored N (%)	P value*	
									Gender
	Male	51±3	44-57	62±14	34-90	51	11	40 (78.4)	
Age	22-54	62±4	55-69	-	-	38	4	34 (89.5)	0.13
	55-87	47±4	40-54	59±10	40-78	44	13	31 (70.4)	
Tumor location	Rectum	50±7	36-63	59±24	13-105	20	5	15 (75)	0.815
	Right colon	49±6	36-61	-	-	21	4	17 (80.9)	
	Transverse	41±5	32-51	-	-	11	2	9 (81.8)	
	Left colon	53±5	43-63	-	-	22	3	19 (86.4)	
Stage	1	-	-	-	-	2	0	2 (100)	0.007
	2	56±3	49-63	-	-	39	4	35 (89.7)	
	3	46±2	41-50	-	-	19	2	17 (89.5)	
	4	38±6	26-51	62±0	-	17	9	8 (47.1)	
Grade	1	49±4	40-57	59±0	-	31	6	25 (80.6)	0.054
	2	38±3	32-43	-	-	33	7	26 (78.8)	
	3	8±1	10-May	6±0	-	2	1	1 (50)	

\* Log rank test

**Table 3. Univariate Analyses of Survival Outcomes by Kras Status, Metastasis and Treatment Type**


Characteristics	Survival time (mean ±SE)	95%CI	Survival time (median ±SE)	95%CI	Total (N)	Number of events (N)	Number of censored (%)	P value	
									Metastasis
	No	61±2	57-65	-	-	46	1	45 (97.8)	
KRAS status	Wild	56±4	48-65	-	-	49	8	41 (83.7)	0.155
	Mutant	47±5	37-56	62±0	-	33	9	24 (72.7)	
Treatment type	1	61±2	57-65	-	-	44	1	43 (97.7)	0.001*
	2	46±7	33-58	59±19	22-96	20	7	13 (65)	
	3	35±7	22-49	27±8	Dec-42	16	9	7 (43.7)	
Outcome	Yes	-	-	-	-	53	0	53 (100)	0.001*
	No	29±5	19-38	22±6	Oct-34	24	17	7 (29)	

\*Log rank test




**Figure 1. Kaplan–Meier Survival Estimates for Colorectal Carcinoma Patients.** A) Overall; B) Stratified by sex; C) Stratified by age; D) Stratified by location

a mutant KRAS. No statistical difference was observed between the patients with mutant KRAS and those with the wild type of the gene in terms of age and gender (Table 1). Wild type KRAS was more expressed in tumors located in rectum (71.4%), in comparison to other anatomical sites involvement( not statistically significant). Patients with metastasis had more expression of mutant type of KRAS (46.2%) in comparison to patients who had not metastasis, but this was not significant. The mean survival rate was  $53 \pm 3$  months (Mean $\pm$ SE) with a (95%CI, 47-60) in the samples examined. The Kaplan-Meier curve showed the probability of survival rate have decreased with a gentle gradient for 57 months after the initial diagnosis, and then there's a steep decrease until month 62 and then plateaued (Figure 1A). According to Table 2, significant correlation was found between survival time and tumor stage (PV=0.007). The survival time had not significant association with patients age, gender, tumor location, grade and type of the gene (Table 3, Figures 1, 2). Patients with metastasis who expressed mutant KRAS (treatment type 3) had a shorter survival time than those with wild type KRAS (treatment type 2) and patients without metastasis (treatment type 1) (PV=0.0001) (Figure 3). Based on the odds ratio (OR), the risk of mortality was found to be 2.02 times higher in patients with mutant KRAS than in those with the wild type of the gene; however, this difference was not statistically significant (PV>0.05).



**Figure 2. Kaplan–Meier Survival Estimates for Colorectal Carcinoma Patients.** A) Stratified by stage (I, II, III, IV); B) Stratified by grades; C) Stratified by metastasis status; D) Stratified by KRAS status



**Figure 3. Kaplan–Meier Survival Estimates for Stratified by Treatment Type**

## Discussion

The present study conducted a statistical analysis of the clinicopathological findings of colorectal adenocarcinoma patients and relationship between KRAS status and the variables such as (gender, age, tumor site, tumor grade, stage of the disease, type of treatment, mean survival rate and prognosis). The only variable significantly related to KRAS status was the stage of the disease. Moreover, a mutant KRAS indicated a worse prognosis for patients than a wild-type KRAS and was also associated with a poorer response to treatment.

Based on literatures, about 30-50% of patients with colorectal cancer appear to have mutant KRAS (Howlander et al., 2012; Kolahdoozan et al., 2010; Dolatkahh 2015). Therefore, the majority of patients respond appropriately to anti-epidermal growth factor receptor treatments (Breivik et al., 1994; Liu X et al., 2011; Arrington 2012; Phipps et al., 2013; Phipps et al., 2015). In our study about 40% of the patients had the mutant form of KRAS, which is consistent with the findings of similar studies (Dolatkahh et al., 2015; Mohammadianpanah et al., 2015; McGrath 1983). In previous studies, the frequency of mutant KRAS expression was almost equal among men and women and no statistically significant differences were reported in the expression of mutant KRAS by gender, which is compatible with the results of the present study (Vauthey et al., 2013). Kito et al., 2015. reported significantly more common KRAS mutations in tumors of the rectum than in tumors of other anatomic regions of the colon.

In the present study, although the expression of mutant KRAS was more common in right colon than in the other regions, the difference was not statistically significant. Previous studies have reported mutant KRAS to be correlated with tumor grade, as the majority of tumors with mutant KRAS were grade 2 (moderately differentiated) (Siyar et al., 2015). In the present study, the highest frequency of mutant KRAS was observed in the moderately differentiated tumors, although this difference was not statistically significant which could be due to small sample size of our study. Tumors with mutant KRAS are diagnosed at more advanced stages, while most tumors diagnosed at early stages have wild-type KRAS. Chang et al., 2014. reported 44% of patients with metastatic colorectal cancer to have KRAS mutations and also found no differences in survival rate between patients with mutant KRAS and those with wild-type KRAS.

In the present study, the frequency of the mutant type of the gene was higher in patients with the metastatic form of the cancer, although no significant relationship was found between gene type and metastasis. In terms of survival, previous studies have reported that about 40-60% of patients with wild-type KRAS do not respond appropriately to this type of treatment, as they also have mutant BRAF genes (Koike et al., 2014; Yammaz et al., 2015). Anti-EGFR therapy, such as a combination of FOLFOX, Panitumumab and Cetuximab, appears to be associated with a good prognosis for patients with wild-type KRAS; patients with this type of the gene also appear to attain a better prognosis when treated with a combination of Cetuximab and FOLFIRI (Rui et

al., 2015; Selcukbiricik et al., 2013). Patients who have used combination therapies have responded better to treatments than those who have used one-drug regimens (Chang et al., 2014; Yanmaz et al., 2015). According to a study conducted by Yoon et al 2014. KRAS mutations are an independent predictive factor for survival as the mutant type of KRAS should be considered a negative predictive factor for patients with metastatic colorectal cancer. In the present study, the risk of mortality was 2.02 higher in patients with the mutant type of the gene than in those who had the wild type of the gene; however, this difference was not statistically significant. Patients with metastatic colorectal cancer who have wild-type KRAS seem to respond more appropriately to a combination treatment with FOLFOX and Cetoximab, as this treatment is associated with a better progression-free survival and overall survival in them compared to those who have the mutant type of the gene and have received the same treatment (Deng et al., 2015). Selcukbiricik et al. (2013) and Kadowaki et al. (2015), found that KRAS and BRAF mutations cannot be considered prognostic factors in patients with metastatic colorectal cancer (Li et al., 2012; Kadowaki et al., 2015). They concluded other factors, such as other mutation subtypes, can be used as strong prognostic factors.

The present study found a significant relationship between treatment regimens and survival rate, as mortality rates were noticed to be higher in patients who received treatment type 3 than in those who received the other two types of treatment. However, this significant difference was not due to the type of treatment regimen, rather to the progression of the disease and its metastasis in the patients. Moreover, this treatment regimen was used only for patients who had the metastatic form of the cancer, and not for patients with wild-type KRAS. Nevertheless, this treatment regimen did not reduce mortality rates. Consequently, survival rate can be said to be more related to the stage of the disease rather than KRAS type. Loupakis et al. in 2015 reported that patients with right colon cancer have a worse prognosis than patients with left colon cancer (Loupakis et al., 2015). The present study also found a higher mean survival rate in patients with tumors in their left colon than in those with tumors in their other anatomic regions; however, this difference was not reported to be statistically significant.

In conclusion, in our study, patients with metastasis who expressed wild type KRAS and were treated by combination of Folfax and Cetuximab had a better survival compared to patients with metastasis expressed mutant type of KRAS and were treated by Folfax and Bevacizumab. Also in our study, the survival time was significantly correlated with tumor stage.

## References

- Allegra CJ, Rumble RB, Hamilton SR, et al (2016). Extended ras gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: american society of clinical oncology provisional clinical opinion update 2015. *J Clin Oncol*, **34**, 179-85.

- Arrington AK, Heinrich EL, Lee W, et al (2012). Prognostic and predictive roles of KRAS mutation in colorectal cancer. *Int J Mol Sci*, **13**, 12153-68.
- Breivik J, Meling GI, Spurkland A, Rognum TO, Gaudernack G (1994). K-ras mutation in colorectal cancer: relations to patient age, sex and tumour location. *Br J Cancer*, **69**, 367-71.
- Chang YY, Lin JK, Lin TC, et al (2014). Impact of KRAS mutation on outcome of patients with metastatic colorectal cancer. *Hepatogastroenterol*, **61**, 1946-53.
- Cunningham D, Atkin W, Lenz HJ, et al (2010). Colorectal cancer. *Lancet*, **375**, 1030-47.
- Deng Y, Wang L, Tan S, (2015). KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer. *Mol Oncol*, **9**, 1341-7.
- Dolatkah R, Somi MH, Kermani IA, et al (2015). Increased colorectal cancer incidence in Iran: a systematic review and meta-analysis. *BMC Public Health*, **15**, 997.
- Ferlay J, Soerjomataram I, Dikshit R, et al (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*, **136**, 359-86.
- Howlander N, Noone AM, Krapcho M, et al (2012). SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Available from: [http://seer.cancer.gov/csr/1975\\_2013](http://seer.cancer.gov/csr/1975_2013).
- Kadowaki S, Kakuta M, Takahashi S, et al (2015). Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer. *World J Gastroenterol*, **21**, 1275-83.
- Kito Y, Yamazaki K (2015). Targeted therapies for metastatic colorectal cancer. *Nihon Rinsho*, **73**, 1384-90 [in Chinese].
- Koike J, Ushigome M, Funahashi K, et al (2014). Significance of KRAS mutation in patients receiving mFOLFOX6 with or without bevacizumab for metastatic colorectal cancer. *Hepatogastroenterol*, **61**, 2222-6.
- Kolahdoozan S, Sadjadi A, Radmard AR, Khademi H (2010). Five common cancers in Iran. *Arch Iran Med*, **13**, 143-6.
- Li Z, Chen Y, Wang D, et al (2012). Detection of KRAS mutations and their associations with clinicopathological features and survival in Chinese colorectal cancer patients. *J Int Med Res*, **40**, 1589-98.
- Lin AY, Buckley NS, Lu AT, Kouzminova NB, Salpeter SR(2011). Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy: a systematic review and meta-analysis. *Clin Colorectal Cancer*, **10**, 63-9
- Liu X, Jakubowski M, Hunt JL (2011). KRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis. *Am J Clin Pathol*, **135**, 245-52.
- Loupakis F, Yang D, Yau L, et al (2015). Primary tumor location as a prognostic factor in metastatic colorectal cancer. *J Natl Cancer Inst*, **107**, 3.
- McGrath JP, Capon DJ, Smith DH, et al (1983). Structure and organization of the human Ki-ras proto-oncogene and a related processed pseudogene. *Nature*, **304**, 501-6.
- Misale S, Yaeger R, Hobor S, et al (2012). Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. *Nature*, **486**, 532-6.
- Mohammadianpanah M (2015). Colorectal cancer incidence: Does Iran follow the West? *Ann Colorectal Res*, **3**, 1.
- Phipps AI, Buchanan DD, Makar KW, et al (2013). KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. *Br J Cancer*, **108**, 1757-64.
- Phipps AI, Limburg PJ, Baron JA, et al (2015). Association between molecular subtypes of colorectal cancer and patient survival. *Gastroenterol*, **148**, 77-87.
- Rui Y, Wang C, Zhou Z, Zhong X, Yu Y (2015). K-Ras mutation and prognosis of colorectal cancer: a meta-analysis. *Hepatogastroenterol*, **62**, 19-24.
- SEER Stat Fact Sheets (2014): Colon and Rectum Cancer. NCI. Retrieved 18 June 2014.
- Selcukbiricik F, Erdamar S, Ozkurt CU, et al (2013). The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer. *J BUON*, **18**, 116-23.
- Shaib W, Mahajan R, El-Rayes B (2013). Markers of resistance to anti-EGFR therapy in colorectal cancer. *J Gastrointest Oncol*, **4**, 308-18.
- Siyar Ekinci A, Demirci U, Cakmak Oksuzoglu B, et al (2015). KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma. *J BUON*, **20**, 128-35.
- Vauthey JN, Zimmitti G, Kopetz SE, et al (2013). RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. *Ann Surg*, **258**, 619-26.
- World Cancer Report (2014). World Health Organization. 2014. pp. Chapter 1.1.
- Yaeger R, Cowell E, Chou JF, et al (2015). RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. *Cancer*, **121**, 1195-203.
- Yanmaz MT, Demir G, Erdamar S, et al (2015). Epidermal growth factor receptor in CRC patients in the era of the RAS. *Hepatogastroenterol*, **62**, 40-4.
- Yoon HH, Tougeron D, Shi Q, et al (2014). KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). *Clin Cancer Res*, **20**, 3033-43.